177 related articles for article (PubMed ID: 19856046)
1. Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan.
Shibata Y; Ariyama H; Baba E; Takii Y; Esaki T; Mitsugi K; Tsuchiya T; Kusaba H; Akashi K; Nakano S
Int J Clin Oncol; 2009 Oct; 14(5):397-401. PubMed ID: 19856046
[TBL] [Abstract][Full Text] [Related]
2. [Clinical features of hypersensitivity reactions to oxaliplatin among Chinese colorectal cancer patients].
Zhao Y; An X; Xiang XJ; Feng F; Wang FH; Wang ZQ; Xu RH; He YJ; Li YH
Chin J Cancer; 2010 Jan; 29(1):102-5. PubMed ID: 20038320
[TBL] [Abstract][Full Text] [Related]
3. Hypersensitivity reactions to oxaliplatin in two asian patients.
Ng CV
Ann Pharmacother; 2005 Jun; 39(6):1114-8. PubMed ID: 15886290
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of mFOLFOX6 as the adjuvant treatment after curative resection of metastases from colorectal cancer in Japanese patients.
Machida N; Yoshizaki K; Boku N; Yamazaki K; Onozawa Y; Fukutomi A; Yasui H; Taku K
Int J Clin Oncol; 2013 Apr; 18(2):279-84. PubMed ID: 22367535
[TBL] [Abstract][Full Text] [Related]
5. High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin.
Kidera Y; Satoh T; Ueda S; Okamoto W; Okamoto I; Fumita S; Yonesaka K; Hayashi H; Makimura C; Okamoto K; Kiyota H; Tsurutani J; Miyazaki M; Yoshinaga M; Fujiwara K; Yamazoe Y; Moriyama K; Tsubaki M; Chiba Y; Nishida S; Nakagawa K
Int J Clin Oncol; 2011 Jun; 16(3):244-9. PubMed ID: 21243395
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer.
Seki K; Senzaki K; Tsuduki Y; Ioroi T; Fujii M; Yamauchi H; Shiraishi Y; Nakata I; Nishiguchi K; Matsubayashi T; Takakubo Y; Okamura N; Yamamori M; Tamura T; Sakaeda T
Int J Med Sci; 2011 Mar; 8(3):210-5. PubMed ID: 21448307
[TBL] [Abstract][Full Text] [Related]
7. Allergic reactions to oxaliplatin in a single institute in Japan.
Ichikawa Y; Goto A; Hirokawa S; Kijima M; Ishikawa T; Chishima T; Suwa H; Yamamoto H; Yamagishi S; Osada S; Ota M; Fujii S
Jpn J Clin Oncol; 2009 Sep; 39(9):616-20. PubMed ID: 19556337
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.
Kang BW; Kim TW; Lee JL; Ryu MH; Chang HM; Yu CS; Kim JC; Kim JH; Kang YK; Lee JS
Med Oncol; 2009; 26(1):32-7. PubMed ID: 18498064
[TBL] [Abstract][Full Text] [Related]
10. Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies.
Sugihara K; Ohtsu A; Shimada Y; Mizunuma N; Lee PH; de Gramont A; Goldberg RM; Rothenberg ML; André T; Brienza S; Gomi K
Clin Colorectal Cancer; 2012 Jun; 11(2):127-37. PubMed ID: 22099928
[TBL] [Abstract][Full Text] [Related]
11. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.
Delaunoit T; Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Findlay BP; Thomas SP; Salim M; Schaefer PL; Stella PJ; Green E; Mailliard JA
Cancer; 2004 Nov; 101(10):2170-6. PubMed ID: 15470715
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR).
Maindrault-Goebel F; de Gramont A; Louvet C; André T; Carola E; Gilles V; Lotz JP; Tournigand C; Mabro M; Molitor JL; Artru P; Izrael V; Krulik M
Ann Oncol; 2000 Nov; 11(11):1477-83. PubMed ID: 11142489
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients.
Nagashima M; Ooshiro M; Moriyama A; Sugishita Y; Kadoya K; Sato A; Kitahara T; Takagi R; Urita T; Yoshida Y; Tanaka H; Oshiro T; Okazumi S; Katoh R
Support Care Cancer; 2014 Jun; 22(6):1579-84. PubMed ID: 24452412
[TBL] [Abstract][Full Text] [Related]
14. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
André T; Bensmaine MA; Louvet C; François E; Lucas V; Desseigne F; Beerblock K; Bouché O; Carola E; Merrouche Y; Morvan F; Dupont-André G; de Gramont A
J Clin Oncol; 1999 Nov; 17(11):3560-8. PubMed ID: 10550155
[TBL] [Abstract][Full Text] [Related]
15. Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience.
Shimizu T; Satoh T; Tamura K; Ozaki T; Okamoto I; Fukuoka M; Nakagawa K
Int J Clin Oncol; 2007 Jun; 12(3):218-23. PubMed ID: 17566846
[TBL] [Abstract][Full Text] [Related]
16. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
Chen ML; Fang CH; Liang LS; Dai LH; Wang XK
Surg Oncol; 2010 Mar; 19(1):38-45. PubMed ID: 19345093
[TBL] [Abstract][Full Text] [Related]
17. [Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer].
Cai Y; Deng R; Hu H; Zhang J; Ling J; Wu Z; Yang L; Li J; Deng Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1045-1050. PubMed ID: 30269326
[TBL] [Abstract][Full Text] [Related]
18. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
Tournigand C; Cervantes A; Figer A; Lledo G; Flesch M; Buyse M; Mineur L; Carola E; Etienne PL; Rivera F; Chirivella I; Perez-Staub N; Louvet C; André T; Tabah-Fisch I; de Gramont A
J Clin Oncol; 2006 Jan; 24(3):394-400. PubMed ID: 16421419
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study).
Kotaka M; Iwamoto S; Satake H; Sakai D; Kudo T; Fukunaga M; Konishi K; Ide Y; Ikumoto T; Tsuji A; Sano Y; Kato T; Sugimoto N; Satoh T; Kanazawa A; Kurata T; Yamanaka T; Tomita N
Int J Clin Oncol; 2020 Aug; 25(8):1515-1522. PubMed ID: 32409917
[TBL] [Abstract][Full Text] [Related]
20. Desensitization to oxaliplatin with two stages of premedication in a patient with metastatic rectal cancer.
Nozawa H; Muto Y; Yamada Y
Clin Ther; 2008 Jun; 30(6):1160-5. PubMed ID: 18640472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]